德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06996 德琪医药-B

休市中 06-26 16:08:11

3.300

-0.050

-1.49%

最高3.600	最低3.220	成交量57.41万
今开3.600	昨收3.350	日振幅11.34%
总市值22.41亿	流通市值22.41亿	总股本6.79亿
成交额188.84万	换手率0.08%	流通股本6.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":3.3,"timestamp":1782461291010,"preClose":3.35,"halted":0,"volume":574057,"delay":0,"changeRate":-0.014925373134328438,"floatShares":679000000,"shares":679000000,"eps":-0.4380713669516116,"marketStatus":"休市中","change":-0.05,"latestTime":"06-26 16:08:11","open":3.6,"high":3.6,"low":3.22,"amount":1888419,"amplitude":0.113433,"askPrice":3.3,"askSize":500,"bidPrice":3.29,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.4495995608187593,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":7,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":3.35,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":0.4103454251123513,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996","defaultTab":"news","newsList":[{"id":"2646844901","title":"德琪医药-B(06996)拟进行市场内股份购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2646844901","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646844901?lang=zh_cn&edition=full","pubTime":"2026-06-25 06:59","pubTimestamp":1782341960,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，其拟根据公司股东于2026年6月10日举行的股东周年大会上授予董事会的一般授权，行使其相关权力，以购回至多6792.44万股公司股份，即于股东周年大会日期已发行股份总数的10%。于2026年6月24日，董事会已决议动用股份购回授权，并根据市况不时于公开市场按最高总代价5000万港元购回股份。董事会认为建议股份购回符合公司及其股东整体最佳利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06996","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646284490","title":"德琪医药-B(06996.HK)拟进行市场内股份购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2646284490","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646284490?lang=zh_cn&edition=full","pubTime":"2026-06-25 06:59","pubTimestamp":1782341960,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1191","06996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073562","title":"德琪医药拟以TCE产品为创新资产“注入”新公司 实现“出海”","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073562","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073562?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:44","pubTimestamp":1782135840,"startTime":"0","endTime":"0","summary":"德琪医药通过将自身的创新资产导入K2，依托K2的跨技术平台与跨地域的药物发现与开发能力，实现“出海”。该模式也被称为中国创新药的“NewCo”“出海”模式。德琪医药是一家成立于2017年的创新药研发公司，该公司的创始人梅建明博士拥有近20年跨国药企肿瘤研发经验。同时，德琪医药始终坚定自主研发。梅建明表示，本次NewCo合作，是德琪全球化战略的关键落地，也为国内Biotech提供全新“出海”范本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-06-22/doc-inieiatn2356680.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-06-22/doc-inieiatn2356680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06996","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645685014","title":"德琪医药-B(06996)与MPM BioImpact创立的K2 Therapeutics就ATG-106达成独家授权协议 并授予其一项未披露双特异性TCE的选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2645685014","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645685014?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:36","pubTimestamp":1782088596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，Antengene Biologics Limited与由K2 Therapeutics新成立的一家公司， 已就ATG-106订立一份独家且可再授权的授权协议。此外， K2与授权方亦已订立一份选择权协议，据此，K2已获授一项独家选择权，以取得一款未披露的临床前双特异性TCE候选药物的独家授权。MPM BioImpact是一家全球领先的生物技术投资机构，拥有逾30年创建及投资创新公司的经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4007","BK4139","LENZ","BK4539","BK1191","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06078","IE00BZ08YR35.GBP","BK1576","LU1226287875.USD","LU1880383366.USD","02162","01548","01801","06996","LU0051755006.USD","02273","LU0502904849.HKD","03692","LU0181495838.USD","SG9999002562.SGD","LU0320764599.SGD","BK1191","LU0140636845.USD","IE00B0JY6N72.USD","LU0819121731.USD","LU2097828631.EUR","03329","02096","01093","LU1960683339.HKD","01952","LU1242518857.USD","06990","LU2399975544.HKD","HK0000320264.USD","00013","02269","02268","09996","LU0456827905.SGD","HK0000306685.HKD","02596","09966","03759","09926","LU0348827113.USD","01177","01951","LU0737861772.HKD","LU1688375341.USD","01530","LU3063872942.SGD","01276","06821","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423894","title":"德琪医药-B(06996)：刘滢及林芊希获委任为公司联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642423894?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:19","pubTimestamp":1781090374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，曹洋先生及黄伟超先生已辞任公司联席公司秘书，均自2026年6月10日起生效。曹洋先生将继续担任集团副总裁并负责资本市场业务。刘滢女士及林芊希女士已获委任为公司联席公司秘书，以接替曹洋先生及黄伟超先生的职务，均自2026年6月10日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK1583","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642418288","title":"德琪医药-B(06996)：ATG-201 (CD19×CD3 TCE)治疗自身免疫性疾病的IND于中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2642418288","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642418288?lang=zh_cn&edition=full","pubTime":"2026-06-10 06:21","pubTimestamp":1781043675,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，中国国家药品监督管理局(国家药监局)已批准ATG-201 (一款CD19/CD3双特异性T细胞衔接器抗体，用于治疗B细胞介导的自身免疫性疾病)的I期研究的新药临床试验(IND)申请。德琪医药计划迅速启动并推进在中国的I期研究，同时正为ATG-201在澳大利亚的临床开发作准备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","BK1583","06996","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155459729","title":"德琪医药-B发布5月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1155459729","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155459729?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:47","pubTimestamp":1780566426,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年6月4日发布截至2026年5月31日的股份变动月报。公告显示，公司当月未发生新增发行或回购注销事项，股本保持稳定。经公告披露，截至5月末，公司法定股本维持在2,000,000,000股普通股，面值每股USD 0.0001，总注册股本USD 200,000。已发行股份为679,244,132股，另有202,500股为库存股份，总计为679,446,632股，较上月无变化。此外，本月内并未因行使期权取得任何资金。公司确认已持续遵守香港联交所《上市规则》及相关法律法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639648279","title":"港股异动 | 德琪医药-B(06996)涨超5% ATG-022 ADC治疗相关胃腺癌关键性III期CLINCH-3研究获临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639648279?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK1191","III","BK4588","ADC","BK4080","BK1583","BK4585","BK4134","06996","BK1574","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632546","title":"德琪医药-B(06996)：ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部(GEJ)腺癌的关键性III期CLINCH-3研究获中国临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632546","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638632546?lang=zh_cn&edition=full","pubTime":"2026-05-28 07:27","pubTimestamp":1779924430,"startTime":"0","endTime":"0","summary":"作为一项关键注册研究，CLINCH-3旨在支持ATG-022作为单药疗法治疗CLDN18.2+晚期胃癌或胃食管结合部腺癌的未来上市许可申请。本集团无法保证ATG-022最终将成功开发及上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","BK4134","BK1583","III","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636938798","title":"德琪医药-B(06996)：侯冰获委任为首席科学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2636938798","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636938798?lang=zh_cn&edition=full","pubTime":"2026-05-20 08:04","pubTimestamp":1779235487,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，公司董事会欣然宣布任命侯冰博士为首席科学官，直接向德琪医药创始人、董事长兼首席执行官梅建明博士汇报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B(06996)：侯冰获委任为首席科学官","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03888","02013","09626","02096","06186","00772","06609","06969","09992","00909","01440","01783","01951","00719","02197","02192","02618","02306","06060","09888","00136","06660","02172","06049","00169","01548","02252","81024","02256","02171","01905","02276","02126","00013","03700","09688","06963","06996","02158","01952","01060","01357","06160","03692","09699","00762","01024","09858","02285","01833"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188860039","title":"德琪医药-B 4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1188860039","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188860039?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:36","pubTimestamp":1778150199,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年5月7日发布2026年4月30日止月份的证券变动月报表。报告显示，公司期内注册股本维持2,000,000,000股，面值每股0.0001美元，注册股本总额仍为200,000美元。已发行股份为679,244,132股，库存股份202,500股，合计679,446,632股，与上月底相同。同时，公司确认符合香港联交所上市规则所规定的公众持股量要求。截至4月末，公司股本结构保持稳定，未见其他股份发行及回购活动。德琪医药-B表示已遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112683220","title":"德琪医药-B2025年收入同比增14.5%至1.05亿元 研发投入下降助推亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1112683220","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112683220?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:21","pubTimestamp":1777454477,"startTime":"0","endTime":"0","summary":"德琪医药-B在截至2025年12月31日止年度中，收入自2024年的人民币0.92亿元增至1.05亿元，同比增长14.5%。年内亏损则由2024年的人民币3.193亿元下降至2.391亿元，经调整后亏损由3.04亿元缩减至2.015亿元，降幅达33.7%，主要系研发等成本的管控效果所致。公司在研发费用方面从2024年的人民币2.589亿元降至1.691亿元；销售及分销开支由7,370万元减少至6,916.2万元；行政开支由1.063亿元降至8,747万元，使整体费用水平下降。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B2025年收入同比增14.5%至1.05亿元 研发投入下降助推亏损大幅收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138551243","title":"德琪医药-B拟回购不超过已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138551243","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138551243?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:18","pubTimestamp":1777454300,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年4月29日发布公告，计划在即将召开的股东周年大会上寻求一般性授权，拟于香港联交所回购不超过已发行股份总数的10%。以最后实际可行日期679,244,132股已发行股份为基准，最高可回购的股份数量约为67,924,413股。根据有关安排，如回购议案获得通过，公司将有权在未来适当时机于香港联交所执行购回操作。为办理大会相关事宜，公司在2026年6月5日至6月10日期间暂停登记过户。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B拟回购不超过已发行股本10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173334840","title":"德琪医药-B更新2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1173334840","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173334840?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:25","pubTimestamp":1775730357,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年4月9日发布2026年3月的股份变动月报表。公告显示，截至3月31日，公司注册股本保持在2,000,000,000股，面值为每股USD 0.0001，总额USD 200,000。本月未出现注册股本增减变动。截至3月31日，公司已发行股份为679,244,132股，库存股份为202,500股，合计679,446,632股，较上月底无变化。本月内未发生新增发行、购回或注销活动，股本总数维持稳定。2022年受限制股份单位计划当月亦有178,000股限制性股票单位失效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625302749","title":"德琪医药-B(06996)授出合共190万份购股权及25万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2625302749","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625302749?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:13","pubTimestamp":1775564039,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，于2026年4月2日，本公司根据2020年股权激励计划向五名承授人授出合共190万份购股权，并根据2022年受限制股份单位计划向其中四名承授人授出25万份受限制股份单位，惟须待承授人接纳并遵守上市规则以及2020年股权激励计划及2022年受限制股份单位计划的各自条款后，方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","06996","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178298832","title":"异动解读 | 德琪医药-B盘中大涨5.81%，执行董事增持及与优时比授权协议提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1178298832","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178298832?lang=zh_cn&edition=full","pubTime":"2026-03-26 10:16","pubTimestamp":1774491406,"startTime":"0","endTime":"0","summary":"德琪医药-B今日盘中股价大幅上涨5.81%，引起了市场的广泛关注。根据协议，德琪医药将获得8000万美元的首付款及近期里程碑付款，并有资格在未来获得最高约11亿美元的里程碑付款以及基于净销售额的分级特许权使用费。此外，分析报告指出，德琪医药作为一家专注于创新抗肿瘤药物的生物制药公司，其2025年度收入同比增长14.5%至1.05亿元人民币，亏损也显著收窄。内部增持与重大利好的授权协议共同作用，提振了市场对公司价值的认可和股价表现。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622020093","title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622020093","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622020093?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:14","pubTimestamp":1774437259,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，3月24日，执行董事龙振国增持德琪医药(06996)23.5万股，每股作价4.136港元，总金额约为97.2万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1574","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622804144","title":"【券商聚焦】交银国际维持德琪医药(06996)买入评级  指其2026年有望盈亏平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2622804144","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622804144?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:13","pubTimestamp":1774415596,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，德琪医药 2025年收入同比+15%至1.05亿元，亏损收窄至2.39亿元。展望2026年，与优时比达成的ATG-201交易有望贡献8,000万美元近期付款，公司预计将显著增厚业绩并实现盈亏平衡，研发投入将有所回升。综合考虑2025全年业绩和ATG-201交易对未来业绩的增厚作用，该机构上调公司2026-27年收入及盈利预测，上调DCF目标价至10港元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977194","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":-0.0294},{"period":"1month","weight":-0.2396},{"period":"3month","weight":-0.3168},{"period":"6month","weight":-0.1771},{"period":"1year","weight":0.1},{"period":"ytd","weight":-0.1293}],"compareEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.1049},{"period":"3month","weight":-0.0914},{"period":"6month","weight":-0.1219},{"period":"1year","weight":-0.068},{"period":"ytd","weight":-0.1154}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.091928},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034689},{"month":5,"riseRate":0.5,"avgChangeRate":0.014763},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.135818},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000904},{"month":8,"riseRate":0.4,"avgChangeRate":-0.030428},{"month":9,"riseRate":0.4,"avgChangeRate":-0.020432},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"德琪医药-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}